Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: results + study + cancer  Related to the article below (Last Update: 8/5/2008)

Epigenomics AG Reports First Half of 2008 Results
FOXBusiness -
Study results are expected to become available in 2009. In Q2 2008, Epigenomics successfully completed two clinical studies in its lung cancer program. ...FRA:ECX - DGX - EBR:ONCOB
Cancer patients often use "complementary methods"
Reuters - 34 minutes ago
The results are reported in the medical journal Cancer. Of 19 CMs included in the survey, the most frequently cited was prayer/spiritual practice, ...
Exposure To Agent Orange Linked To Prostate Cancer In Vietnam Veterans
Science Daily (press release) -
"Here we report on the largest study to date of Vietnam War veterans exposed to Agent Orange and the incidence of prostate cancer." Chamie also said that, ...
Leukemia Journal Publishes Results from Darinaparsin Study
MarketWatch - Aug 4, 2008
announced today the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of ...
NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA ...
MarketWatch -
... results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer ...
YM BioSciences says Phase II data for nimotuzumab supports ... Hemscott
all 29 news articles »  YMI
Craig W. Philips Takes Helm at CTI
FOXBusiness -
OPAXIO is also being studied independently in a phase III trial for ovarian cancer, with interim data results expected in late 2009. ...CTIC - OTC:CMTX
Breast cancer: What you need to know
Food Consumer, IL -
A study recently found that turmeric may have the potential of stopping the spread of breast cancer. The results were presented in the fourth Era of Hope ...
Neoprobe Announces Second Quarter Results
FOXBusiness -
Obtained clearance from FDA to commence patient enrollment in a Phase 3 clinical study to evaluate the efficacy of Lymphoseek in patients with breast cancer ...OTC:NEOP
FDA Reviewing Biomoda Submission for Cancer Screening Study
MarketWatch - Aug 4, 2008
Approval by the Agency of the results of this study that we expect early next year will provide us the ability to market our assay commercially. ...OTC:BMOD
OXiGENE Reports Second Quarter 2008 Results
FOXBusiness - Aug 4, 2008
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is ...OXGN - OTC:CMTX
Source: Google News

… as adjuvant treatment in rectal cancer. Final results of a randomized study of the European … -
A G?rard, M Buyse, B Nordlinger, J Loygue, F P?ne … - Annals of Surgery, 1988 - pubmedcentral.nih.gov
... in rectal cancer. Final results of a randomized study of the European
Organization for Research and Treatment of Cancer (EORTC). ...

… external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III … -
M Bolla, L Collette, L Blank, P Warde, JB Dubois, … - The Lancet, 2002 - Elsevier
... LG Smith and JA Antonlak, Preliminary results of a randomized dose-esacalation study
comparing 70 Gy to 78 Gy for the treatment of prostate cancer, Int J ...

Breast cancer and hormone-replacement therapy: the Million Women Study -
V Beral, E Banks, G Reeves, D Bull - The Lancet, 2003 - Elsevier
... 3 Cmmittee on Safety of Medicines, Hormone replacement therapy (HRT) and breast
cancer: results of the UK Million Women Study (http://www.mhra.gov.uk). ...

… and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European … -
T Le Chevalier, D Brisgand, JY Douillard, JL Pujol … - Journal of Clinical Oncology, 1994 - jco.ascopubs.org
... for stage IV non-small-cell lung cancer: docetaxel-cisplatin ... agent docetaxel or
vinorelbine at progression: final results of a randomised phase II study Ann. ...

… , operations, and medications: case control results from the Melbourne Colorectal Cancer Study -
GA Kune - Cancer Research, 1988 - AACR
... ARTICLES. Colorectal cancer risk, chronic illnesses, operations, and medications:
case control results from the Melbourne Colorectal Cancer Study. ...

… Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening Study -
NF Boyd, JW Byng, RA Jong, EK Fishell, LE Little, … - jnci, 1995 - jnci.oxfordjournals.org
... Quantitative Classification of Mammographic Densities and Breast Cancer Risk:
Results From the Canadian National Breast Screening Study. ...

… Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer … -
H Mouridsen, M Gershanovich, Y Sun, R Perez- … - Journal of Clinical Oncology, 2001 - jcojournal.org
... as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results
of a Phase III Study of the International Letrozole Breast Cancer Group. ...

… Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study -
PW Kantoff, S Halabi, M Conaway, J Picus, J … - Journal of Clinical Oncology, 1999 - jcojournal.org
... Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate
Cancer: Results of the Cancer and Leukemia Group B 9182 Study. ...

… First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen … -
J Bonneterre, B Thurlimann, JFR Robertson, M … - Journal of Clinical Oncology, 2000 - jcojournal.org
... Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of
the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. ...

… Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study -
PM Hoff, R Ansari, G Batist, J Cox, W Kocha, M … - Journal of Clinical Oncology, 2001 - jcojournal.org
... Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients
With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study. ...

Source: Google Scholar

Drug study for brain cancer shows promising results

DETROIT – A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

The randomized Phase II study focused on patients with glioblastoma multiforme (GBM), whose cancer had recurred after first- or second-line therapy. The study revealed that more than a third who were treated with Avastin (bevacizumab) alone, as well as more than half of those treated with Avastin in combination with the chemotherapy drug irinotecan, lived without further progression of the disease for a period of six months. In addition, no new or unexpected adverse effects from the use of Avastin were observed during the study.

“This is very encouraging news,” says Tom Mikkelsen, M.D., a neuro-oncologist who is the study’s principal investigator at Henry Ford and co-director of the Hermelin Brain Tumor Center. "Historical estimates suggest that only 15 percent of patients with this aggressive type of brain cancer live without their cancer progressing within six months. Although gliomas [fast-growing malignant brain tumors] are nearly always incurable, use of a drug like Avastin may help to buy precious time for patients, as well as to preserve their physical and mental functions longer than was previously possible.”

Avastin is a therapeutic antibody designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that stimulates development of new blood vessels in a process known as angiogenesis, while maintaining existing tumor vessels. By binding to VEGF, Avastin acts as an anti-angiogenesis agent that chokes off the blood supply to tumors, which in turn inhibits their growth and metastasis.

The national study is sponsored by Genentech and Henry Ford Hospital is one of the large study sites.

“The same process that makes gliomas so deadly may turn out to be exactly the same thing that makes it possible to slow down their progression,” Dr. Mikkelsen says. "This is a very significant advance in the battle to control these aggressive tumors because it could lead to treatment options where none existed previously for patients with recurrent disease.”

Previously Avastin had been used in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer and lung cancer. Because of its demonstrated success rate with these cancers, Avastin currently is being studied worldwide in more than 300 clinical trials for 20 different tumor types.

“With currently approved therapies, the chances of suppressing GBM are poor at less than 10 percent,” says Dr. Mikkelsen. “This type of targeted therapy using Avastin may prove to be the best new hope we have for helping patients with recurrent disease who previously had few options available to them.”

According to the American Cancer Society (ACS), the five-year survival rate for patients with GBM is 3 percent, a figure that has not changed in more than 25 years. The ACS estimates there will be 20,500 new cases of brain cancer and 12,740 brain cancer deaths in 2007.

###
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.